Is It Rejection – or Something Else? - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Is It Rejection – or Something Else?

  • By

  • Jessica Allerton

  • November 17, 2026

  • 6 min

Share

Objective:

The article examines the objective, findings, and clinical context described in Is It Rejection – or Something Else?.

Approach:
  • Testing methods: Biopsy-based molecular tests measure gene expression in tissue; other assays examine blood or urine for patterns associated with rejection or injury.
  • Example: MMDx Kidney uses microarray gene-expression measurements and an organ-specific reference dataset to estimate the probability of molecular patterns associated with rejection or injury.
Key Findings:
  • Biopsy and histology remain central, but biopsies sample only a small part of the organ and some findings can be difficult to interpret consistently.
  • Creatinine and estimated glomerular filtration rate indicate kidney function but do not identify why it has changed.
  • Molecular patterns may provide additional information when microscopic changes are subtle, but they do not always establish the cause of injury.
  • Rejection, infection, medication toxicity, reduced blood flow, obstruction, and recurrence of the original disease can cause graft dysfunction and may require different management.
  • Donor-specific antibodies indicate an immune response associated with increased risk but do not alone confirm active rejection.
  • Blood- and urine-based biomarkers are under investigation; current evidence does not support their universal use as replacements for biopsy.
Interpretation:

Molecular testing can add information about biological activity in sampled tissue and may help narrow possible causes of graft injury. Its role in guiding treatment or medication dosing is still being established.

Limitations:
  • Biopsy sampling covers only a small portion of the kidney and molecular analysis cannot map the entire organ.
  • Histology is an imperfect reference standard; interpretations can vary, and some findings occur in multiple conditions.
  • A molecular test trained to reproduce histologic diagnoses may inherit limitations of those diagnoses.
  • Diagnostic accuracy and clinical benefit are separate questions; test performance should be assessed in independent samples and, ideally, prospective studies.
  • No single test result provides a definitive answer.
Conclusion:

The article presents molecular testing as complementary to biopsy, routine laboratory tests, and clinical assessment. It notes that further evidence is needed to establish how molecular and less invasive biomarker tests should guide clinical decisions.

Sources:

Original Source(s)

Related Content